Study compares criteria for monitoring response to CRC treatment

04/11/2013 | MolecularImaging.net

The PET Response Criteria in Solid Tumors and criteria from the European Organization for Research and Treatment of Cancer are similarly useful for measuring the response of patients with colorectal cancer to cycles of irinotecan and cetuximab using PET/CT, according to a study published in The Journal of Nuclear Medicine. However, the researchers found that PERCIST was better suited for widespread use because the criteria were less sensitive to differences between observers, allowing for greater consistency.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC